Cargando…

Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD

INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membrano...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanset, Nicolas, Esteve, Emmanuel, Plaisier, Emmanuelle, Johanet, Catherine, Michel, Pierre-Antoine, Boffa, Jean-Jacques, Fievet, Patrick, Mesnard, Laurent, Morelle, Johann, Ronco, Pierre, Dahan, Karine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056852/ https://www.ncbi.nlm.nih.gov/pubmed/32154454 http://dx.doi.org/10.1016/j.ekir.2019.12.006

Ejemplares similares

Efficacy of Rituximab in a Patient With Partial Clinical Remission and Persistent Circulating PLA2R-Ab
por: Georges, Elodie, et al.
Publicado: (2019)

Serum Albumin Still of Interest to Predict Outcomes in Membranous Nephropathy in the Era of Phospholipase A2 Receptor
por: Delafosse, Marion, et al.
Publicado: (2020)

Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients
por: Michel, Pierre-Antoine, et al.
Publicado: (2011)

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy
por: Dahan, Karine, et al.
Publicado: (2017)

Advances in Membranous Nephropathy
por: Ronco, Pierre, et al.
Publicado: (2021)

Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy
por: Berchtold, Lena, et al.
Publicado: (2017)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Extracorporeal shock wave therapy does not improve hypertensive nephropathy
por: Caron, Jonathan, et al.
Publicado: (2016)

Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy
por: Muruve, Daniel A., et al.
Publicado: (2022)

Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy
por: Dähnrich, Cornelia, et al.
Publicado: (2019)

Persistent Aseptic Pyelonephritis After Acute Bacterial Pyelonephritis: Possible Role of Corticosteroids
por: Tamzali, Yanis, et al.
Publicado: (2022)

Corrigendum to Persistent Aseptic Pyelonephritis After Acute Bacterial Pyelonephritis: Possible Role of Corticosteroids Kidney International Reports, Volume 7, Issue 8, August 2022, Pages 1897-1900
por: Tamzali, Yanis, et al.
Publicado: (2022)

Exome-First Strategy in Adult Patients With CKD: A Cohort Study
por: Doreille, Alice, et al.
Publicado: (2022)

Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years
por: Pourcine, Franck, et al.
Publicado: (2017)

Circulating antibodies to α-enolase and phospholipase A(2) receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy
por: Kimura, Yukihiro, et al.
Publicado: (2016)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
por: Van Meerhaeghe, Tess, et al.
Publicado: (2022)

CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2016)

Guide de la télédetection spatiale en France
por: Johanet, Pierre
Publicado: (1989)

Bilateral Kidney Infarction Due to Primary AL Amyloidosis: A First Case Report
por: Mihout, Fabrice, et al.
Publicado: (2015)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Etiologies, Clinical Features, and Outcome of Oxalate Nephropathy
por: Buysschaert, Benoit, et al.
Publicado: (2020)

Nephrotic syndrome associated with immune thrombocytopenia revealing Kimura's disease in a non-Asian male
por: Noel, Nicolas, et al.
Publicado: (2009)

Non-Randall proliferative glomerulonephritis with humps and monotypic IgG deposits in primary Sjögren’s syndrome: a first case report
por: Dahan, Karine, et al.
Publicado: (2010)

Membranous nephropathy: current understanding of various causes in light of new target antigens
por: Ronco, Pierre, et al.
Publicado: (2021)

Urinary peptidome analysis in CKD and IgA nephropathy
por: Li, Zewen, et al.
Publicado: (2023)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Experimental Aristolochic Acid Nephropathy: A Relevant Model to Study AKI-to-CKD Transition
por: Baudoux, Thomas, et al.
Publicado: (2022)

Anti-phospholipase A2 receptor antibodies in membranous nephropathy
por: Lee, Sangho
Publicado: (2018)

The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes
por: Saïdi, Michèle, et al.
Publicado: (2021)

24-h Urine Collection: a Relevant Tool in CKD Nutrition Evaluation
por: Abdel-Nabey, Moustafa, et al.
Publicado: (2020)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Noninvasive screening of vancomycin-associated cast nephropathy
por: Rafat, Cédric, et al.
Publicado: (2022)

Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab
por: Demoulin, Nathalie, et al.
Publicado: (2021)

Management of Undocumented Immigrants With End-Stage Kidney Disease in 2 Academic Hospitals in Paris
por: Le Flécher, Arnaud, et al.
Publicado: (2021)

CKD of Unknown Origin in Central America: The Case for a Mesoamerican Nephropathy
por: Correa-Rotter, Ricardo, et al.
Publicado: (2014)

Impact of pretreatment with carnitine and tadalafil on contrast-induced nephropathy in CKD patients
por: Armaly, Zaher, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p4qudc2041pnto6hg7jq5ju81c